Short Bowel Syndrome Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Short Bowel Syndrome (SBS) Market studied was anticipated to grow with a CAGR of nearly 29.8%, during the forecast period. The major factors attributing to the growth of the SBS market are rise in global prevalence of GI disorders like volvulus, Inflammatory bowel disease (IBD), in particular, Crohn’s disease (CD), which predisposes patients to development of SBS and mesenteric ischemia are the most common causes for SBS among all the age groups which demand the necessity of the treatment.

Additionally, the increased awareness programs led by several associations like the Association of gastrointestinal motility, Oley Foundation and the SBS Cure Project coupled with rising in the government health care expenditure are likely to drive the market growth over the forecast period.

Key Market Trends

GLP-2 Drug Therapy by Drug Class is Expected to Hold the Largest Market Share During the Forecast Period

The GLP-2 drug treatment accounts for the major market share throughout the forecast period. The dominance is due to the only products available for treatment with the brand names Gattex and Revestive, introduced by Takeda which were approved for sales in both the US and Europe respectively. Also, the patent exclusivity of GLP-2 drug is anticipated to contribute to its significant share in the revenue of the global short bowel syndrome market.

By distribution channels, hospital pharmacies are accounted for the highest market share due to the rapid implementation of therapy due to a huge patient pool. Also, the preference by the patients due to unaffordability and higher expensive parenteral nutrition along with prescription products contribute to a major share in the global short bowel syndrome market.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall Short Bowel Syndrome Market throughout the forecast period. This dominance is mainly due to the revenue generated by the Gattex, the only glucagon-like peptide-2 (GLP-2) analog approved that improves intestinal absorption in patients with SBS in the U.S. Also, rise in the sedentary lifestyle that led no time to focus on nutritious and healthy food with increased consumption of unhealthy and junk food, resultant intestinal disorders are a major factor that drives the market growth in the region.

The Asia Pacific is anticipated to grow at the fastest rate during the forecast period due to the huge patient pool in China and India, and the uncontrolled consumption of antibiotics in India. Also, the research activities and investments on R&D in the region are estimated to fuel the growth of the SBS market in the Asia Pacific and attribute to a significant share in global market.

Competitive Landscape

The global short bowel syndrome market is moderately competitive and consists of several prominent industry players. Some prominent players are making partnerships and acquiring the blockbuster products in the market, other companies and expanding their market position globally. For instance, Takeda acquired the Shire, to expanding its geographic footprint and to be a leader in providing targeted treatments in gastroenterology, the leading companies in gastroenterology (GI) and neuroscience. While other key players are focusing on distributing and manufacturing of over-the-counter dietary supplements. Whereas, some companies such as Naia Pharmaceuticals SBS, Micelle BioPharma, Inc. are having new products in their pipeline. Some of the companies which are currently dominating the market are TAKEDA Inc, Naia Pharmaceuticals Inc, VectivBio AG, OxThera Inc, and Nutrinia Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support